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Gonadotropins extracted from the urine of post-menopausal women have traditionally been used to stimulate
folliculogenesis in the treatment of infertility and in assisted reproductive technology (ART). Products, such as
human menopausal gonadotropin (hMG), consist not only of a mixture of the hormones, follicle-stimulating
hormone (FSH), luteinising hormone (LH) and human chorionic gonadotropin (hCG), but also other biologically active
contaminants, such as growth factors, binding proteins and prion proteins. The actual amount of molecular LH in hMG
preparations varies considerably due to the purification process, thus hCG, mimicking LH action, is added to standardise
the product. However, unlike LH, hCG plays a different role during the natural human menstrual cycle. It is secreted by
the embryo and placenta, and its main role is to support implantation and pregnancy. More recently, recombinant
gonadotropins (r-hFSH and r-hLH) have become available for ART therapies. Recombinant LH contains only LH
molecules. In the field of reproduction there has been controversy in recent years over whether r-hLH or hCG should
be used for ART. This review examines the existing evidence for molecular and functional differences between LH
and hCG and assesses the clinical implications of hCG-supplemented urinary therapy compared with recombinant
therapies used for ART.
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The human gonadotropins, luteinising hormone (LH),
follicle-stimulating hormone (FSH) and human chori-
onic gonadotropin (hCG), are complex heterodimeric
glycoprotein hormones that each play pivotal, though
differing, roles in the female reproductive system. Nor-
mal ovarian function depends on the concerted action of
FSH and LH, both of which are produced in the anterior
pituitary. According to the two-cell two-gonadotropin
theory, these hormones — together with local steroidal
and non-steroidal factors — stimulate follicular growth
and maturation, ovulation, and the development of the
corpus luteum [1] (Figure 1).
In contrast, hCG only becomes important once there
is an embryo, such that hCG produced by the develop-
ing embryo takes over from LH in the upregulation of* Correspondence: diego.ezcurra@emdserono.com
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article, unless otherwise stated.the corpus luteum progesterone production. Between 3
and 4 weeks after implantation, the placenta becomes
capable of progesterone production independently of
hCG and the role of hCG then changes to one focused
on the promotion and maintenance of the maternal
blood supply to the developing foetus. This is achieved
through hCG binding to the LH/hCG receptors on the
uterine spiral arteries and the subsequent promotion of
angiogenesis. Additionally, hCG is involved in the differ-
entiation of placental cells, prevention of rejection of
foetal-placental tissue and the promotion of uterus
growth in line with foetal growth [2].
While LH and FSH are each single molecular entities,
hCG exists in a number of different molecular forms [2,3].
In addition to regular hCG, variants include sulphated pitu-
itary hCG that is present at low levels during the menstrual
cycle and in post-menopausal women; a hyperglycosylated
form that promotes growth and invasiveness of cytotro-
phoblast cells during embryo implantation and ind Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Hormones act in concert to regulate normal ovarian function.
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factor produced in many malignancies. These functional
and molecular differences between LH and hCG suggest
that there may be differences in the clinical efficacy of the
two gonadotropins.
Historically in the treatment of infertility and in
assisted reproductive technology (ART), urinary human
menopausal gonadotropin (hMG) from post-menopausal
women has been used to stimulate folliculogenesis.Over the years, a number of working hypotheses have
developed concerning the advantages and disadvan-
tages of the various exogenously added gonadotropin
supplements used in ART, particularly with respect
to hMG. Although urinary-derived hMG contains both
FSH and LH, the LH content is highly variable and
hMG is supplemented with urinary hCG, which is
intended to mimic the action of LH and to standardise
the product.
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duce recombinant forms of human FSH (r-hFSH) and
LH (r-hLH). These are now available as potential alter-
natives to hMG and may be more suitable in those sub-
populations of patients requiring the addition of LH in
their stimulation protocols. This is of particular rele-
vance given the increasing recognition of the need for
individualised controlled ovarian stimulation (iCOS) to
maximise the benefit for patients.
The aim of this review is to present evidence from
both laboratory-based, in vitro and clinical studies in
order to identify any differences between LH and hCG
at the molecular and functional levels and to examine
the implications that these differences may have on clin-
ical outcomes.
Review
The nature of hCG-containing hMG products
The origin of hCG in hMG
A commonly held belief is that all the hCG contained in
high-purity hMG (HP-hMG) comes naturally from the
urine of post-menopausal women and that no exogenous
hCG is added to these HP-hMG treatments. However,
there is evidence to show that as the purity of a hMG
preparation is increased, more LH molecules are prefer-
entially lost [4] and more exogenous hCG needs to be
added to return to the required FSH:LH ratio of 1:1 in
the original product [5]. In a study of commercially
available urinary hMG products [4], the older less puri-
fied products (e.g. Pergonal) contained more endogen-
ous LH and less exogenous hCG (Table 1). In contrast,
the majority of LH bioactivity in HP-hMG was provided
by hCG supplementation [4]. In earlier analyses of thisTable 1 LH and hCG content (immunoreactivity) of
different urinary hMG preparations
Product LH IU/vial (SD) hCG IU/vial (SD) LH/hCG
ratio
Study
Pergonal 13.49 (3.6) 3.39 (1.7) 3.98 Wolfenson
et al. [4]
Humegon 5.77 (1.0) 6.86 (1.8) 0.84 Wolfenson
et al. [4]
Menopur 0.29 (5.2) 9.61 (2.3) 0.03 Wolfenson
et al. [4]
Menopur 0.48 (1.7) 9.05 (3.3) 0.05 Wolfenson
et al. [4]
Menopur 0.39 (3.1) 11.06 (1.8) 0.04 Wolfenson
et al. [4]
Menopur 0.85 (0.18) 11.3 (1.0) 0.08 Giudice
et al. [6]
Menopur 3 (range 2.7–5.3) 10 (range 9.9–11.2) 0.03 Van de Weijer
et al. [5]
hCG human chorionic gonadotropin; IU international units; LH luteinising
hormone; hMG human menopausal gonadotropin.same HP-hMG, Giudice et al. [6] found the hCG con-
tent to be 10-fold higher than that of LH, while van de
Weijer et al. [5] reported three times as much immuno-
reactive hCG to be present as LH (Table 1). The au-
thors of the latter study concluded that 95% of the LH
bioactivity in the HP-hMG was due to the presence of
hCG. Although post-menopausal women release core
β-fragments of hCG in urine, van de Weijer et al. [5]
concluded that the relatively high amount of hCG
in the HP-hMG can only be explained by assuming the
addition of hCG from external sources, a well-
established practice in the production of hMG for
standardisation purposes. This means that when hCG is
added to hMG to increase its LH bioactivity, the vari-
ability in “real LH” content and the significantly longer
half-life of hCG make it more difficult to control the
administered product. In contrast, pure LH, sources of
which include r-hLH alone or in combination with r-
hFSH, allow for more precise dosing and physiological
action to control follicular development.
The purity of hMG
Eight purification steps, including hormone absorption
and elution, anion and cation exchange, and hydropho-
bic chromatography are used in the preparation of HP-
hMG. Despite this, urinary hMG products not only
contain hCG, but also relatively high percentages of
other protein impurities and these impurities vary be-
tween batches [5,6]. Van de Weijer et al. [5] used reverse-
phase high-performance liquid chromatography (HPLC)
analysis and 2D gel electrophoresis to identify at least
30% protein impurities in an hMG preparation, including
leucocyte elastase inhibitor, protein C inhibitor, and zinc-
α2-glycoprotein.
Other studies have also found contaminant proteins
such as growth factors, glycoproteins, binding proteins,
transferrin, and immunoglobulins that are not reported
to induce follicular development and which may in-
fluence the efficacy and possible safety of hMG
products [7,8]. Some of the contaminants identified
were highlighted as being biologically active (e.g. epi-
dermal growth factor [EGF], tumour necrosis factor
binding protein-1 and Tamm–Horsfall glycoprotein).
Their presence exposes patients to possible adverse
effects [7]. For example EGF is a potent mitogenic
factor, not normally present in the follicular phase of
the ovulation cycle that induces stromal and epithe-
lial cell proliferation and differentiation. While
in vitro studies have reported that EGF increases
cumulus cell numbers and oocyte maturation [9], the
exogenous EGF in hMG could interfere with the
normal process of cell proliferation and differenti-
ation in endometrial cells by synergising with other
growth factors and replacing the actions of
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like factors reported to play roles in oocyte develop-
ment and ovulation [10].
Another potential contaminant of hMG, insulin-like
growth factor (IGF)-binding protein-7 regulates cellular
proliferation, adhesion, and angiogenesis, and may sup-
press oestrogen production by granulosa cells [11]. None
of these contaminants appear to confer any proven ad-
vantage in terms of clinical outcome and, moreover, the
concentration and type of impurities varies considerably
between batches [6].
Of particular interest are two recent proteomic ana-
lyses of the composition of urinary-derived hMG, hCG
and HP-hMG that detected the presence of prion pro-
teins [12,13]. Van Dorsselaer et al. [13] identified prion
protein as a ‘major contaminant’ of hMG preparations,
while prion proteins were not detected in recombinant
products. Prions are a mis-folded isoform of a normal
cellular protein found in the brain (PrPc), and are associ-
ated with transmissible spongiform encephalopathies
(TSEs). When a prion comes into contact with another
native version of this protein, it induces the native pro-
tein to adopt the mis-folded shape. As the body is un-
able to recognise and break down the abnormally folded
protein, prions accumulate in the central nervous sys-
tem, interfering with normal brain function. Conversion
of PrPc into the abnormal form can occur spontaneously
or following infection. Abnormal prions have been iden-
tified including PrPsc, which is the protein associated
with scrapie, and PrPres, the protein resistant to enzyme
degradation found in patients with Cruetzfeldt-Jacob dis-
ease (CJD) [14].
Although the studies by Kuwabara et al. [12] and Van
Dorsselaer et al. [13] showed that prion proteins can be
detected in urinary-derived fertility preparations includ-
ing hMG, there is no strong evidence to support the
suggestion that vCJD (or sporadic CJD) has been ac-
quired through receiving urinary gonadotropins [15].
The risk of TSE from urinary products has even been
described as unproven or theoretical [16,17]. However,
as described by Van Dorsselar in the absence of evidence
for no risk of urinary TSE transmission, the precaution-
ary principle should be considered for urinary-derived
preparations [13]. In the end when treating patients for
ART we intended to inject only gonadotropins like FSH,
LH and hCG but not contaminants, to act at the level of
the ovarian axis, develop follicles and mature oocytes
that will be retrieved for later fertilization and the pro-
duction of embryos for transfer.
Comparison of LH and hCG at the molecular level
While hCG can mimic the bioactivity of LH, there are
differences between LH and hCG at the molecular level.
However, both are members of the cystine-knot growthfactor families of highly glycosylated, non-covalently
linked α- and β-subunits that exhibit the properties
of cytokines and chemokines [18]. LH originates from
the pituitary gland and is a heterodimeric glycopro-
tein with a molecular mass of 28 kDa comprising
alpha (92 amino acids) and beta (120 amino acids)
subunits. Whereas hCG, also a heterodimer, is com-
posed of 244 amino acids with a molecular mass of
36.7 kDa.
Different cell types produce different forms of hCG.
Regular hCG is produced by the placental syncitiotro-
phoblasts and hyperglycosylated hCG is produced by
stem cytotrophoblastic cells, while sulphated hCG is
made in small amounts by the pituitary and the free
β-subunit is produced by non-trophoblastic malignan-
cies [2,19]. The alpha subunit of hCG comprises 92
amino acids and is almost identical to that of LH
[18]. Although the α-subunits of LH and hCG show a
high degree of similarity, the β-subunit is unique to
each hormone. As well as containing an extra 24
amino acids, the β-chain of hCG possesses additional
glycosylation sites, eight for hCG compared with
three for LH. The extra glycosylation sites give hCG
a longer half-life (terminal half-life via the subcutane-
ous route of 32–33 hours for recombinant hCG vs
21–24 hours for r-hLH [20,21]). It is the β-subunit of
the hormone that confers its specificity and particular
physiological activity [22].
Comparison of the functional properties of LH and hCG
Roles in follicular development
Some proponents believe that hCG is ideal for fol-
licular development because its long half-life provides
a more sustained LH stimulation. Recombinant LH,
in contrast, has a shorter half-life and, according to
some authors, requires multiple daily injections to
sustain follicle development [2]. In addition, hCG has
a higher binding affinity for the receptor and is more
potent [23]. These observations have led to the as-
sumption that the more hMG (containing hCG) is
added during stimulation, and the earlier that this oc-
curs (i.e. at day 1), the more favourable the outcome
will be.
Although binding to the same receptor, LH and
hCG play different physiological roles within ovula-
tion and pregnancy. These differing roles are reflected
by the timing of each hormone’s appearance in the
ovulation cycle [2]. Initially, FSH acts on the granu-
losa cells [24] of the ovary to stimulate follicular de-
velopment and the aromatisation of androgens for the
production of oestradiol while LH interacts with the
theca cells for androgen production, the raw material
for oestrogen synthesis. At a follicle size of 8–12 mm,
under the effect of FSH the granulosa cells express LH
Figure 2 LH immunoassay concentrations over time after three
routes of administration. Log-linear plot of LH immunoassay
concentrations over time after Single IV (solid line), IM (long dashed
line), and SC short dashed line administration of 10,000 IU of r-hLH
(mean ± 1 SEM, 12 subjects). Reprinted from Fertil Steril, 69, le
Cotonnec JY, Porchet HC, Beltrami V, Munafo A, Clinical pharmacology
of recombinant human luteinizing hormone: Part II. Bioavailability of
recombinant human luteinizing hormone assessed with an
immunoassay and an in vitro bioassay, pages 195–200, Copyright
1998, with permission from Elsevier [20].
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major role in follicular growth and oocyte maturation.
The surge of LH at mid-cycle induces ovulation, re-
sumption of meiosis in the oocyte [25], formation of
the corpus luteum, luteinisation of the theca and
granulosa cells, and early progesterone synthesis [26].
Unlike LH, hyperglycosylated hCG is produced by the
trophoblastic cells of the early embryo (days 4–6) to
stimulate the corpus luteum to progesterone production
and initiation of the implantation process. After 3–4
weeks the placenta starts to produce progesterone [2].
The placenta then takes over hCG production and hCG
levels peak after 10 weeks of gestation.
LH and hCG possess significantly different in vitro
biopotencies, despite binding to the same receptor, as
shown in a study using COS-7 cells expressing the
LH/hCG receptor [23]. In this study, the effective
dose at 50% (ED50) of the maximal cyclic adenosine
monophosphate (cAMP) response was approximately
5-fold greater with hCG than with equimolar concen-
trations of LH. In addition, use of equipotent ED50
concentrations of LH and hCG showed that the
cAMP response to LH reached a plateau after 10 mi-
nutes vs 1 hour for hCG. Continuous exposure to LH
and hCG for 12 hours revealed repetitive and pulsatile
increases in cAMP activation every 3–4 hours and
significantly higher levels of stimulation by hCG com-
pared with LH [23].
In addition to these pharmacodynamic differences, the
pharmacokinetics of LH and hCG are also quite differ-
ent. After intravenous (IV) administration, the pharma-
cokinetics of r-hLH follow a two-compartment model,
while after subcutaneous (SC) administration (Figure 2),
the pharmacokinetics of r-hLH can be described
by using a one-compartment model with zero-order
absorption and a lag time [20]. Following IV admin-
istration, r-hLH undergoes a rapid distribution phase
with an initial half-life (distribution half-life) of ap-
proximately 1–1.3 hours (as assessed by immuno-
assay and in vitro bioassay), and a slower elimination
phase with a terminal half-life (elimination half-life)
of around 10–19 hours [20]. After SC administra-
tion, the terminal half-life was approximately 21–24
hours as assessed by immunoassay and in vitro bio-
assay. With an effective half-life of approximately
1 day, r-hLH is suitable for once-daily SC injections
resulting in only a modest accumulation of 1.6 IU/L
of LH with repeated daily administration of 150 IU
of LH [20]. In contrast, the terminal half-life of
hCG is 32–34 hours [21], leading to the possibility
of drug accumulation. Indeed, patients treated
with 50 IU/day of hCG showed measurable and in-
creasing levels of hCG over the course of a treat-
ment cycle to 16.2 ± 3.2 IU/L of hCG, which isequivalent to 113.4 IU/L of LH activity [27]. The accu-
mulation of hCG over the ovulation cycle can lead to in-
creased interaction at the LH/hCG receptor level. This is
of importance since a threshold level of 1.2 IU/L of LH is
required for optimal follicular development [28,29].
There is a ‘ceiling’ LH level (5 IU/L) above which granu-
losa cell proliferation is suppressed and atresia (of the
non-dominant follicles) and premature luteinisation (of
the pre-ovulatory follicle) occurs [30,31].
High levels of LH also lead to desensitisation and
down regulation of the LH receptors [32,33]. This occurs
transiently under physiological conditions (the pre-
ovulatory LH surge) or in response to pharmacological
doses of hCG [34]. Down regulation of the LH/hCG re-
ceptor is mediated by the accelerated degradation of LH/
hCG receptor mRNA caused by the LH receptor mRNA
binding protein mevalonate kinase [33]. This has been
confirmed in gene expression studies where there was
consistently lower expression of the LH/hCG receptor
gene in granulosa cells from women undergoing con-
trolled ovarian hyperstimulation who were treated with
hMG compared with those treated with r-hFSH [32].
Thus, the high levels of hCG contained in hMG, to-
gether with its longer half-life, may lead to an undesir-
able accumulation of LH-like bioactivity with possible
premature luteinisation and reduced fertilisation rates
[35] or to a reduced response as a result of LH/hCG re-
ceptor desensitisation.
A summary of the molecular and functional differ-
ences between LH and hCG is shown in Table 2.
Table 2 Differences between LH and hCG
LH hCG
Secreted by Pituitary Embryo and placenta
Physiological role Support follicle development (14 days) Support implantation and pregnancy (282 days)
Binding affinity Lower Higher (2x)
Half-life Shorter (23 h sc) Longer (32–33 h sc)
Accumulation Slight Significant and down regulation of LH receptor
Stimulation of LH receptor Physiological Pharmacological, leading to LH receptor down
regulation
Equivalency 6–8 IU of LH 1 IU of hCG
Purity 99% 99% purity for r-hCG and 70% in HP-hMG
(39 identified contaminants)
Sources r-hLH r-hCG, urinary hCG or hMG
Induction of steroid (testosterone, oestradiol
and progesterone) production
Higher LH = higher steroid production Higher hCG = higher steroid production
Filling system Filled by mass Filled by Mass for r-hCG and Filled
by IU for hCG/hMG
Gene activation Differential unexplained Differential unexplained
Cytokine production Differential unexplained Differential unexplained
Embryo quality production Not objectively proven Not objectively proven
h hours; hCG human chorionic gonadotropin; IU international units; LH luteinising hormone; sc subcutaneous.
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The majority of circulating progesterone is produced in
the intrafollicular compartment by the granulosa cells
and the main driver of progesterone production is in-
creased LH/hCG receptor activity. There is a general
assumption that the hCG present in hMG provides LH-
like activity, supporting the conversion of intrafollicular
progesterone to estradiol. It is thought that this process
cannot happen when using only r-hFSH, due to the lack
of an LH component. However, several studies have
shown that ART is successful with the administration
of r-hFSH only, possibly due to the persistence of low
levels of endogenous LH in the women treated despite
the use of GnRH analogues [36-40].
Conversion of intrafollicular progesterone to oestradiol
at the time of triggering final follicle maturation enables
the endometrium to be more receptive to embryo im-
plantation. This suggests that the conversion of proges-
terone to oestradiol, due to the effect of the hCG
contained in hMG, may lead to better outcomes than
r-hFSH alone. This theory originated from an under-
powered post-hoc analysis of a subpopulation by the
MERIT study, which found that higher serum hCG
levels correlated with lower progesterone and higher
pregnancy rates [41]. However, the enzymes cytochrome
17a-hydroxylase-C17,20 lyase (P450-17α) (converts free
progesterone to oestradiol) and 3-β-hydroxysteroid de-
hydrogenase [3βHSD] (converts pregnenolone to proges-
terone) are localised to the ovarian thecal/interstitial cells
and do not exist in the follicular compartment [42]. This
finding suggests that progesterone cannot be convertedto oestradiol in the follicular compartment. Further,
in a comparative study of the use of urinary hMG
with r-hFSH, Wolfenson et al. [4] found that proges-
terone levels produced in an in vitro follicle bioassay
were 2–3 times higher with hMG than with either
urinary FSH or r-hFSH.
Association between progesterone levels and clinical
outcomes
In contrast to the MERIT study, a subsequent retro-
spective study by Andersen et al. [43] reported a positive
correlation between progesterone levels and the number
of follicles and oocytes. Possible reasons for the discrep-
ancy between these results and those of the MERIT
study include a higher starting dose of FSH in the
MERIT study [41,43].
A more recent large multicentre randomised con-
trolled trial of hMG vs r-FSH reported a significant de-
crease in pregnancy rate with increased progesterone
level [44]. In this study, in the r-FSH group, women with
progesterone levels >4 nmol/L had a significantly lower
pregnancy rate compared with those women with pro-
gesterone levels ≤4 nmol/L, while in the hMG group,
pregnancy rates were similar in women with progester-
one levels ≤4 nmol/L or >4 nmol/L [44]. Other studies
have shown that a higher progesterone/oestradiol ratio
is not associated with lower pregnancy rate and, in
particular, embryo implantation is favoured, due to
lower uterine contractility [45,46]. A further study of
r-hFSH/r-hLH vs HP-hMG and urinary FSH reported
that serum and intra-follicular progesterone levels and
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groups [47].
A randomised, controlled trial by Thuesen et al. [48],
examined serum progesterone in women treated with
increasing doses of hCG (0–50–100–150 IU) in combin-
ation with 150 IU of r-hFSH. In this study, supplementa-
tion with increasing doses of hCG from the first day
exponentially increased pre-ovulatory progesterone and
hydroxy-progesterone [48]. Moreover, in response to a
Letter to the Editor, the authors concluded that the key
importance of their study was to show that in the hCG
dose range of 0–150 IU/day, supplementation with hCG
did not seem to reduce but rather to increase late fol-
licular phase progesterone levels [49]. Pregnancy rates
were not reported in this study.
Overall while these studies demonstrate that serum
progesterone increases with LH or hCG use, threshold
level and timing of progesterone increase and it's clinical
implications of this increase remain unclear.
Intrafollicular cumulus gene expression and cytokine
profiling
One study has concluded that the hCG contained within
hMG supports the production of a different profile of
cytokines and different gene expression in the cumulus
and endometrial cells, generating a better environment
to produce healthier oocytes compared with r-hLH [50].
The upregulated cytokines are known promoters of im-
plantation and angiogenesis and are anti-apoptotic.
However, hCG, with its long half-life and greater
receptor affinity, is likely to exceed the LH ‘ceiling’, a
situation causing atresia of non-dominant follicles and
LH/hCG receptor down regulation. In a comparison of
gene expression studies in women undergoing controlled
ovarian stimulation (COS) with either r-hFSH or hMG,
there was a consistently lower expression level of the
LH/hCG receptor gene in granulosa cells from the hMG
treatment group compared with the r-hFSH group. Sev-
eral genes involved in the biosynthesis of cholesterol and
steroids were also differently regulated and showed re-
duced expression in the granulosa cells of the hMG-
treated group [32]. This group of subjects also showed
increased expression of the S100 calcium-binding p gene
encoding an anti-apoptotic protein.
Another gene expression study of cumulus cells from
patients treated with HP-hMG or r-hFSH also reported
significant differences in gene expression involved in
ovulation, fertilisation, EGF signalling and embryonic de-
velopment depending upon the treatment [51]. Patients
treated with rFSH had increased SPROUGHTY4 but
lower SDC4 levels when compared with hMG-treated
patients. In the same study, the expression of oocyte ma-
turity (VCAN), progesterone and embryo development
on day 3 (GREM1) and RPS6KA2 was related to factorssuch as age in the rFSH treated patients but not in the
hMG treated patients. The authors concluded that the
presence of LH bioactivity in the hMG preparation
might have led to a ‘damping effect on LH responsive
genes’ [51].Production of high-quality embryos
It has been suggested that due to the hCG content, hMG
produces fewer oocytes, however, they are of better quality
than those stimulated with r-hFSH alone or the addition of
r-hLH. Day 6 hCG concentration has been shown to pre-
dict the frequency of top-quality embryos, ongoing preg-
nancy and live birth rates [50]. However, single point
morphological assessments of embryo quality — such as
cell number, degree of fragmentation and symmetry — are
subjective and imprecise and while these assessments can
provide certain clues about quality, they are not able to ob-
jectively assess the physiological state, viability or implant-
ation potential of an embryo. There is no standardised
embryo grading system employed to date, and although
there are reports describing subjective embryo selection
methodologies which result in high implantation rates
[41,52,53], these are not reproducible from one laboratory
to another. Indeed morphological grading can vary dramat-
ically in the course of a few hours, as shown by time-lapse
observations of single embryos, and can be misleading with
respect to categorising the stage of development reached
[54,55]. Therefore, objective technologies are required to
identify high-quality embryos that will increase the chance
of producing successful pregnancies and live births.
Recent studies using gene expression profiling have
made advances in the identification of potential biomarkers
to identify oocytes that should produce top-quality em-
bryos. Paracrine activity between the oocyte and the cumu-
lus cells is essential to ensure the competence of the
developing oocyte and subsequent embryonic development
[56]. Thus, initial studies focused on gene expression pro-
filing of the cumulus cells at specific phases of oocyte de-
velopment [51,57-61] or at varying stages of oocyte
maturation [62] using a variety of genes as potential bio-
markers of embryo development. In one such study HAS2,
PTGS2 and GREM1 expression by cumulus cells corre-
lated with the number of higher grade embryo [60]. In-
creased expression of the Pentraxin 3 gene has also been
identified as being of potential relevance for identifying
good quality embryos [63]. Later studies have provided
data on the gene expression of oocytes themselves. One
study showed that genes related to cell cycle regulation,
chromosome alignment, sister chromatid separation, oxi-
dative stress and ubiquitination were different between
younger and older oocytes [64]. A further review of human
embryo gene expression profiles revealed that components
of the Wnt and transforming growth factor-β signalling
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development [65].
Genomic markers of oocyte viability appear to be bet-
ter with r-hFSH and r-hLH compared with hMG. r-hLH
supplementation in a long GnRH agonist protocol has
been shown to reduce granulosa cell apoptosis as mea-
sured by DNA fragmentation rate and caspase-3 activity
(p <0.01) compared with either r-hFSH or urinary FSH/
urinary hCG, indicating the production of higher quality
oocytes [66]. In a recent study on the use of r-hFSH vs
hMG, Wathlet et al. [67] concluded that gene expression
profiling could be used to identify top-quality oocytes.
SDC4 and TRPM7 gene expression at days 3 and 5
were identified as being the most predictive for good
embryos in the FSH-treated women while VCAN gene
expression had a negative predictive value. In addition,
a significant upregulation of PTGS2 and a non-significant
trend for increased ITPKA was observed in the FSH
group [68].
Clinical effects of LH supplementation
As discussed in the previous section, it has been sug-
gested that due to the hCG content of hMG, fewer
but better quality oocytes are produced, leading to
high quality embryos, better endometrial receptivity and
higher implantation leading to improved live birth rates
[50]. However, to date no studies of sufficient power
have been performed to compare the effects of LH and
hCG on pregnancy and take-home baby rates. The im-
pact of r-hLH administration in oocyte donors on clin-
ical pregnancy rates in recipients was reported in a
study by Acevedo et al. [69]. Oocyte and embryo quality,
and fertilisation and implantation rates were all signifi-
cantly higher in recipients of embryos from donors re-
ceiving r-hFSH and r-hLH plus gonadotropin-releasing
hormone (GnRH) antagonist compared with r-hFSH and
GnRH antagonist alone. The clinical pregnancy rate was
also higher with r-hLH supplementation (51% vs 30%),
although this difference was not statistically significant.
A subsequent comparison of the effect of r-hLH and
r-hFSH reported a trend for increased implantation
with the use of r-hLH compared with r-hFSH [66]. A
lower apoptosis rate was also detected in the r-hLH-
treated patients. Subsequent studies supported the use of
r-hLH to improve the outcome of ART [67,70]. The
addition of r-hLH to r-hFSH resulted in increased im-
plantations in women under 35 (from 14.2% to 23.2%,
p = 0.05) and, although not significant, an increase in
live births in this age group from 24.4% to 28.9% [67].
Paterson et al. [70] further confirmed the importance
of LH supplementation for increased pregnancy and
birth rates. This large, retrospective study of 1565
in vitro fertilisation (IVF) or intra-cytoplasmic sperm
injection (ICSI) cycles found the rates of pregnancy(61% and 54%, p = 0.006) and live births (49% and
42%, p = 0.01) for the use of a combination of r-hLH and
r-hFSH, and r-hFSH alone, respectively. Improvements in
fertilisation and implantation were also observed.
Some previous studies investigating the effect of ex-
ogenous r-hLH had concluded that there was no benefit
in terms of increased pregnancy rates [71-73]. However,
it is, possible that the relatively low numbers in the
study by Kolibianakis et al. [71] were insufficient to
reach clinical significance. While Mochtar et al. [72]
reported no significant difference with r-hLH supple-
mentation; these authors did find that there was a
trend for r-hLH to have a beneficial effect especially a
reduced rate of early pregnancy loss in poor-responders.
GnRH agonist down-regulated women with baseline LH
levels <0.5 mIU/ml undergoing ART, treated with r-hLH,
in addition to r-hFSH, had a lower intrafollicular concen-
tration of vascular endothelial growth factor (VEGF), a
marker of apoptotic potential), elevated oestradiol levels,
and increased fertilisation and pregnancy rates compared
with women receiving r-hFSH alone [74]. The addition
of r-hLH also increased the production of follicular
adiponectin [75], which may enhance follicular insulin
sensitivity, potentially leading to lower insulin levels
and decreased androgens, resulting in a better follicu-
lar environment. In contrast to the above reports, in a
comparison between the use of hCG and r-hLH in
women having at least 2 previous failed attempts at preg-
nancy, the number of follicles and oocytes and implant-
ation and pregnancy rates were higher in the women
receiving hCG [76].
A review of the literature, performed in 2012, on the
use of exogenous LH in ART concluded that there was
insufficient evidence for the general use of exogenous
LH in GnRH antagonist cycles or the benefit of LH and
hCG protocols. However, the authors suggested that
poor responders and women over 35 years old may
benefit from the administration of exogenous r-hLH
[77]. The benefits of the addition of r-hLH in such spe-
cific sub-populations was confirmed in the latest and lar-
gest meta-analysis of 40 randomised, controlled trials of
6443 patients treated with r-hLH/r-hFSH vs FSH only,
in women aged 18–45 years or older. The study showed
significantly more oocytes were retrieved in poor re-
sponders treated with r-hFSH plus r-hLH vs r-hFSH
alone (n = 1077; weighted mean difference +0.75 oocytes;
95% confidence interval [CI] 0.14–1.36). A significantly
higher clinical pregnancy rate was observed with r-hLH/
r-hFSH vs r-hFSH alone in the overall population (risk
ratio [RR] 1.09; 95% CI 1.01–1.18). This difference was
greater in poor responders (n = 1779; RR 1.30; 95% CI
1.01–1.67; intention-to-treat) [78].
A randomised trial of 96 patients undergoing IVF-ICSI
showed that levels of amphiregulin — which have been
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closer to those seen physiologically following the initi-
ation of an endogenous LH surge by a GnRH agonist
than with hCG [79]. This study also showed that signifi-
cantly more metaphase II oocytes (+14%) and transfer-
able embryos (+11%) were obtained with the GnRH
agonist than with hCG. Moreover, a Cochrane review
conducted in 2011 examined all randomised controlled
trials (42 trials, 9606 couples) of rFSH vs urinary derived
gonadotropins [80]. This review concluded that the dif-
ferences in effectiveness and safety between the therapies
were small.
A more recent matched pair study [81] of women re-
ceiving either r-hLH/r-hFSH or hMG during COS showed
that pregnancy rates per cycle (p = 0.006; p = 0.022) and
per embryo transfer (p = 0.025; p = 0.008), and implant-
ation rate per embryo transferred (p <0.001; p <0.001)
were significantly higher in the group treated with r-hLH/
r-hFSH. Fábregues et al. also showed that the oocyte
yield and the number of fertilised oocytes was higher in
women treated with r-hFSH/r-hLH during COS com-
pared with those treated with HP-hMG [82]. However,
in that study, implantation and pregnancy rates were
similar between groups. Finally, more oocytes were
retrieved from women aged 18–35 years treated with
r-hLH/r-hFSH compared with hMG in a recent pro-
spective study [47].
The effect of LH supplementation may be more appar-
ent in poor ovarian responders [83]. In a prospective
study of mature oocytes and live birth rates in women
treated with r-hLH/r-hFSH, HP-hMG or FSH, the num-
ber of mature oocytes and live birth rates were higher
with LH-FSH than hMG and FSH in poor ovarian re-
sponders [83]. Further, a meta-analysis of seven rando-
mised controlled trials of r-hLH/r-hFSH vs FSH only, in
women aged 35 years or older, showed higher clinical
pregnancy rates in those treated with r-hLH/r-hFSH
[84]. While there was criticism of the detailed reporting
of the meta-analysis, the overall conclusions drawn from
these analyses were not materially altered [85]. These
findings may help to explain the difference in outcomes
of previous studies comparing the efficacy of r-hLH/r-
hFSH and HP-hMG.
Cost effectiveness of r-hLH compared with hCG
There are few current data to establish the cost effective-
ness of r-hLH compared with hCG. The acquisition cost
of r-hLH per treatment is certainly higher than that of
HP-hMG. However, a recent cost-effectiveness study
performed in Italy [86], found that due to higher preg-
nancy rates with –hFSH/r-hLH, the cost per preg-
nancy was higher for HP-hMG (€5,439.80) compared
with r-hLH (€3,990.00). In support of this, a study by
Carone et al. reported higher pregnancy rates in womenreceiving r-hFSH/r-hLH vs HP-hMG (58% vs 22% preg-
nancies in the first cycle respectively) [87].
Conclusions
In this review we have described the differences in the
structure and function of the gonadotropins LH and
hCG, and have discussed how these differences may im-
pact on the clinical outcomes of the use of recombinant
or urinary therapies for ART.
In the natural cycle, the role of LH is to support
normal follicular development over the course of ap-
proximately 14 days. In contrast, the natural physio-
logical function of hCG is to support implantation
and pregnancy over the course of approximately
9 months. However, when urinary ART therapies are
used, hCG is added to urinary hMG to replace LH
lost during the purification process and to standard-
ise the therapy. While hCG has LH-like activity, it
differs compared with LH in its potency and dur-
ation of action. The pharmacological dose of hCG in
hMG may lead to excessive LH-like activity causing
premature luteinisation, reduced fertilisation rates,
and down regulation of the LH/hCG receptor ex-
pression in the follicular compartment.
r-hLH contains 99% pure LH, while the most advanced
hMG available contains a mixture of FSH, LH and hCG
with ~30% impurities, including significant biologically
active contaminants such as growth factors, binding
proteins and, importantly, prion proteins. Furthermore,
the presence of other cytokines and molecules with
biological reactivity may adversely affect successful
pregnancy.
LH and hCG directly increase androgen and progester-
one production and, thus, indirectly the production of
oestrogens. However, intrafollicular progesterone is a
terminal product that cannot be converted to oestradiol
by LH or hCG due to lack of 3βHSD and P450-17α.
The lack of objective biomarkers of embryo viability
makes it impossible to define a clear relationship be-
tween embryo quality and LH/hCG. However, the clin-
ical evidence suggests that r-hLH may provide a more
physiological support of follicle development in those
categories of patients who require it. According to
current thinking, patient subpopulations that may bene-
fit from real LH supplementation include patients with
hypogonadotrophic hypogonadism, patients who have
profound LH suppression in a long GnRH agonist proto-
col, patients with a suboptimal response to FSH alone
(9–25% of patients) and some patients older than
35 years.
Overall, while there is some clinical evidence to dem-
onstrate differences between real LH and hCG for ovar-
ian stimulation in ART, there is still a need for further
randomised, controlled trials to provide clarification of
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